The Association of the British Pharmaceutical Industry (ABPI) has appointed John Kearney as President of the Association. He will take up office on 24 April 2015. John replaces Jonathan Emms who is stepping down as President following a promotion within Pfizer which sees him relocating to the US.
09 Feb 2015 Posted in News Release By Press Office
John Kearney, General Manager UK and Ireland at Amgen, has 35 years of experience in the pharmaceutical industry. He held UK and international roles at GlaxoSmithKline and international roles at Pfizer before joining Amgen in 2007.
An economics graduate, John has been on the Board of the ABPI since 2008 where he has worked on a number of key initiatives including leading the Association’s pricing team in negotiations with the Department of Health to secure the 2014 PPRS.
Welcoming John to the role, Stephen Whitehead, CEO of ABPI said: “I am delighted to be working alongside John as President. His unique experience and expertise across the industry will be crucial as he leads the ABPI and the UK pharmaceutical industry through the opportunities and challenges in 2015.”
John Kearney added:
“I am delighted to be building on the recent leadership of Jonathan Emms, at a time when the pharmaceutical industry as a whole is delivering such a high quality and quantity of new science and treatment innovations. I look forward to playing my part in ensuring those innovations are able to make a real difference in the funding and provision of health services, in the outstanding work of healthcare professionals in the UK, and – ultimately – to patients. I am committed to playing my part by listening to all those involved in planning and providing health services in the UK, and leading the ABPI in its engagement with them.”
Current President, Jonathan Emms, has been promoted to Global Marketing Lead within the Global Established Pharmaceutical Business, based in New York. He will step down as ABPI President at the Association’s Annual General Meeting on 23 April.
Stephen Whitehead said:
“It is with sadness that we say goodbye to Jonathan so soon but he leaves with our very best wishes for a fantastic new role and life in America. Jonathan is a passionate and committed leader of the industry and there is no doubt that we are in a better position today thanks to his leadership and collaboration with key health partners.”
Jonathan Emms added:
“It’s been a great privilege to serve as ABPI president and I’m proud of what has been achieved during my tenure. The industry is recognised as a key sector for growth in the UK, but despite this we are operating against a backdrop of Government austerity measures and an NHS budget under significant pressure. This has made for a challenging discussion with Government over pricing, access and uptake. It is imperative that the one-off austerity contribution made by industry through the PPRS is met with good faith by the Government, which must re-double its efforts to ensure that the agreement results in improved access to modern medicines.
“I have every confidence that John will do a great job in leading the ABPI as it continues the work to improve access and uptake of innovative medicines for UK patients, and achieve Government’s aspiration of making the UK a leader in life sciences.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811